A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia

Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Alzheimer's disease; Dementia; Lewy body disease; Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 07 Aug 2017 According to an Axovant Sciences media release, top-line results from the study are expected in fourth quarter 2017.
    • 08 Jun 2017 Results are expected in 2017.
    • 08 Jun 2017 Trial design presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top